Gab2 expression in glioma and its implications for tumor invasion

References

• Butowski NA, Sneed PK, Chang SM. Diagnosis and treatment of recurrent high-grade astrocytoma. J Clin Oncol 2006;24:1273–80.
   PubMed Web of Science ®Google Scholar
• Nishida K, Hirano T. The role of Gab family scaffolding adapter proteins in the signal transduction of cytokine and growth factor receptors. Cancer Sci 2003;94:1029–33.
   PubMed Web of Science ®Google Scholar
• Hibi M, Hirano T. Gab-family adapter molecules in signal transduction of cytokine and growth factor receptors, and T and B cell antigen receptors. Leuk Lymphoma 2000; 37:299–307.
   PubMed Web of Science ®Google Scholar
• Gu H, Neel BG. The “Gab” in signal transduction. Trends Cell Biol 2003;13:122–30.
   PubMed Web of Science ®Google Scholar
• Wohrle FU, Daly RJ, Brummer T. Function, regulation and pathological roles of the Gab/DOS docking proteins. Cell Commun Signal 2009;7:22.
   PubMed Web of Science ®Google Scholar
• Bocanegra M, Bergamaschi A, Kim YH, Miller MA, Rajput AB, Kao J, et al. Focal amplification and oncogene dependency of GAB2 in breast cancer. Oncogene 2010; 29:774–9.
   PubMed Web of Science ®Google Scholar
• Wang Y, Sheng Q, Spillman MA, Behbakht K, Gu H. Gab2 regulates the migratory behaviors and E-cadherin expression via activation of the PI3K pathway in ovarian cancer cells. Oncogene 2012;31:2512–20.
   PubMed Web of Science ®Google Scholar
• Horst B, Gruvberger-Saal SK, Hopkins BD, Bordone L, Yang Y, Chernoff KA, et al. Gab2-mediated signaling promotes melanoma metastasis. Am J Pathol 2009;174: 1524–33.
   PubMed Web of Science ®Google Scholar
• Lee SH, Jeong EG, Nam SW, Lee JY, Yoo NJ, Lee SH. Increased expression of Gab2, a scaffolding adaptor of the tyrosine kinase signalling, in gastric carcinomas. Pathology 2007;39:326–9.
   PubMed Web of Science ®Google Scholar
• Xu XL, Wang X, Chen ZL, Jin M, Yang W, Zhao GF, et al. Overexpression of Grb2-associated binder 2 in human lung cancer. Int J Biol Sci 2011;7:496–504.
   PubMed Web of Science ®Google Scholar
• Zatkova A, Schoch C, Speleman F, Poppe B, Mannhalter C, Fonatsch C, et al. GAB2 is a novel target of 11q amplification in AML/MDS. Genes Chromosomes Cancer 2006;45: 798–807.
   PubMed Web of Science ®Google Scholar
• El-Habr EA, Tsiorva P, Theodorou M, Levidou G, Korkolopoulou P, Vretakos G, et al. Analysis of PIK3CA and B-RAF gene mutations in human astrocytomas: Association with activation of ERK and AKT. Clin Neuropathol 2010;29:239–45.
   PubMed Web of Science ®Google Scholar
• Soslow RA, Dannenberg AJ, Rush D, Woerner BM, Khan KN, Masferrer J, et al. COX-2 is expressed in human pulmonary, colonic, and mammary tumors. Cancer 2000; 89:2637–45.
   PubMed Web of Science ®Google Scholar
• Zhang B, Gu F, She C, Guo H, Li W, Niu R, et al. Reduction of Akt2 inhibits migration and invasion of glioma cells. Int J Cancer 2009;125:585–95.
   PubMed Web of Science ®Google Scholar
• Zhang B, Ma Y, Guo H, Sun B, Niu R, Ying G, et al. Akt2 is required for macrophage chemotaxis. Eur J Immunol 2009;39:894–901.
   PubMed Web of Science ®Google Scholar
• Takino T, Nakada M, Miyamori H, Yamashita J, Yamada KM, Sato H. CrkI adapter protein modulates cell migration and invasion in glioblastoma. Cancer Res 2003;63:2335–7.
   PubMed Web of Science ®Google Scholar
• Liu L, Wu J, Ying Z, Chen B, Han A, Liang Y, et al. Astrocyte elevated gene-1 up-regulates matrix metalloproteinase-9 and induces human glioma invasion. Cancer Res 2010; 70:3750–9.
   PubMed Web of Science ®Google Scholar
• Clemmons DR. Modifying IGF1 activity: An approach to treat endocrine disorders, atherosclerosis and cancer. Nat Rev Drug Discov 2007;6:821–33.
   PubMed Web of Science ®Google Scholar
• Miller BS, Yee D. Type I insulin-like growth factor receptor as a therapeutic target in cancer. Cancer Res 2005;65: 10123–7.
   PubMed Web of Science ®Google Scholar
• Xavier CP, Rastetter RH, Blömacher M, Stumpf M, Himmel M, Morgan RO, et al. Phosphorylation of CRN2 by CK2 regulates F-actin and Arp2/3 interaction and inhibits cell migration. Sci Rep 2012;2:241.
   PubMed Web of Science ®Google Scholar
• Wang N, Feng Y, Lau EP, Tsang C, Ching Y, Man K, et al. F-actin reorganization and inactivation of rho signaling pathway involved in the inhibitory effect of Coptidis Rhizoma on hepatoma cell migration. Integr Cancer Ther 2010;9:354–64.
   PubMed Web of Science ®Google Scholar
• Bernard O. Lim kinases, regulators of actin dynamics. Int J Biochem Cell Biol 2007;39:1071–6.
   PubMed Web of Science ®Google Scholar
• Sun ZF, Wang L, Gu F, Fu L, Li WL, Ma YJ. [Expression of Notch1, MMP-2 and MMP-9 and their significance in glioma patients]. Zhonghua Zhong Liu Za Zhi 2012;34: 26–30.
   PubMedGoogle Scholar
• Toker A, Yoeli-Lerner M. Akt signaling and cancer: Surviving but not moving on. Cancer Res 2006;66:3963–6.
   PubMed Web of Science ®Google Scholar
• Bibollet-Bahena O, Almazan G. IGF-1-stimulated protein synthesis in oligodendrocyte progenitors requires PI3K/mTOR/Akt and MEK/ERK pathways. J Neurochem 2009; 109:1440–51.
   PubMed Web of Science ®Google Scholar
• Yu J, Li J, Zhang S, Xu X, Zheng M, Jiang G, et al. IGF-1 induces hypoxia-inducible factor 1alpha-mediated GLUT3 expression through PI3K/Akt/mTOR dependent pathways in PC12 cells. Brain Res 2012;1430:18–24.
   PubMed Web of Science ®Google Scholar
• Jiang H, Shang X, Wu H, Gautam SC, Al-Holou S, Li C, et al. Resveratrol downregulates PI3K/Akt/mTOR signaling pathways in human U251 glioma cells. J Exp Ther Oncol 2009;8:25–33.
   PubMedGoogle Scholar
• Yan B, Kong M, Chen S, Chen YH. VEGF stimulation enhances Livin protein synthesis through mTOR signaling. J Cell Biochem 2010;111:1114–24.
   PubMed Web of Science ®Google Scholar
• Tran TT, Uhl M, Ma JY, Janssen L, Sriram V, Aulwurm S, et al. Inhibiting TGF-beta signaling restores immune surveillance in the SMA-560 glioma model. Neuro Oncol 2007;9:259–70.
   PubMed Web of Science ®Google Scholar
• Esteve PO, Tremblay P, Houde M, St-Pierre Y, Mandeville R. In vitro expression of MMP-2 and MMP-9 in glioma cells following exposure to inflammatory mediators. Biochim Biophys Acta 1998;1403:85–96.
   PubMed Web of Science ®Google Scholar
• Chien CS, Shen KH, Huang JS, Ko SC, Shih YW. Antimetastatic potential of fisetin involves inactivation of the PI3K/Akt and JNK signaling pathways with downregulation of MMP-2/9 expressions in prostate cancer PC-3 cells. Mol Cell Biochem 2010;333:169–80.
   PubMed Web of Science ®Google Scholar
• Chinni SR, Sivalogan S, Dong Z, Filho JC, Deng X, Bonfil RD, et al. CXCL12/CXCR4 signaling activates Akt-1 and MMP-9 expression in prostate cancer cells: The role of bone microenvironment-associated CXCL12. Prostate 2006;66:32–48.
   PubMed Web of Science ®Google Scholar
• Chetty C, Lakka SS, Bhoopathi P, Rao JS. MMP-2 alters VEGF expression via alphaVbeta3 integrin-mediated PI3K/AKT signaling in A549 lung cancer cells. Int J Cancer 2010;127:1081–95.
   PubMed Web of Science ®Google Scholar
• Zhang D, Brodt P. Type 1 insulin-like growth factor regulates MT1-MMP synthesis and tumor invasion via PI 3-kinase/Akt signaling. Oncogene 2003;22:974–82.
   PubMed Web of Science ®Google Scholar